Answers are grounded in this paper and cite their sources.
The present study was carried out to investigate hypoglycemic activity of Alstonia boonei stem bark extract in experimental mice. Forty mice divided into four (A, B, C and D) groups of ten mice per group were used. Group 1 served as control and were given distilled water in quantities equivalent to highest volume of extract administered while groups 2, 3 and 4 were given streptozotocin (STZ) injection (60mg/Kg), stem bark extract of A. boonei (100mg/Kg) and glibenclamide (2.5mg/Kg bwt) respectively. Diabetes mellitus was induced in groups B, C and D by intraperitoneal injection of STZ (60mg/Kg). The animals in group B were left untreated while those in groups C and D were administered aqueous stem bark extract (100mg/Kg) of A. boonei orally by orogastric intubulation and glibenclamide (2.5mg/Kg) respectively. The administration of the extract commenced two weeks post STZ injection and continued for four weeks. The mice in group B (untreated diabetic) showed some behavioral changes ranging from sluggishness to polyuria which was also accompanied by reduced body weight and elevated blood glucose level. Administrations of A. boonei stem bark to diabetic group of mice (group C) caused a decrease in blood glucose level close to that of control and also reduced the specific activity of hepatic glucose-6-phosphatase (44%) and fru-1, 6-phosphatase (40%) with concomitant increased activity of glucose-6-phospahate dehydrogenase (30.5%). These findings suggest that A. boonei stem bark extract possess hypoglyceamic properties via decreased production of regulatory hepatic glucogenic enzymes.
No takes yet. Share an insight, caveat, or question.
Akinloye et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: